News from GRAFTYS and Juvisé Pharmaceuticals

ORPHELIA Pharma announces the filing of a European Marketing Authorization Application for Kigabeq®
27 February 2018
ORPHELIA Pharma strengthens its capital base and accelerates its development
31 January 2018

News from GRAFTYS and Juvisé Pharmaceuticals

OTONNALE announces the sale of its stake in GRAFTYS, a medtech company involved in orthopedic devices. The purchase of GRAFTYS shares was executed in the last months of 2017 by a Belgian holding set up by Enrico Bastianelli, former CEO of Bone Therapeutics.

OTONNALE also indicates that Juvisé Pharmaceuticals has fully reimbursed the convertible bonds issued in 2011.

We wish these two companies a full success in their next development stages.